Erratum: The risk of inflammatory bowel disease-related colorectal carcinoma is limited: Results from a nationwide nested case-control study (American Journal of Gastroenterology (2011) 106 (319-328) DOI: 10.1038/ajg.2010.428);The risk of inflammatory bowel disease-related colorectal carcinoma is limited: Results from a nationwide nested case-control study

American Journal of Gastroenterology

Volumn 106, Issue 2, 2011, Pages 319-328

  Baars, J E ^a   Looman, C W N ^a   Steyerberg, E W ^a   Beukers, R ^b   Tan, A C I T L ^c   Weusten, B L A M ^d   Kuipers, E J ^a   Van Der Woude, Christien J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^d ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; ENTERITIS; FEMALE; FOLLOW UP; GENERAL HOSPITAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NETHERLANDS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RECTUM POLYP; RISK FACTOR; SCLEROSING CHOLANGITIS;

EID: 79751528883     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.242     Document Type: Erratum

References (45)

1. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-35. (Pubitemid 32234798)
2. Eaden J. Review article: colorectal carcinoma and inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20 (Suppl 4): 24-30. (Pubitemid 39319243)
3. Jess T, Gamborg M, Matzen P et al. Increased risk of intestinal cancer in Crohn ' s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 2005; 100: 2724-9.
4. Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol 2008; 14: 3937-47.
5. Rutter M, Saunders B, Wilkinson K et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451-9. (Pubitemid 38182302)
6. Ekbom A, Helmick C, Zack M et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323: 1228-33. (Pubitemid 20366527)
7. Broome U, Lofb erg R, Veress B et al. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995; 22: 1404-8.
8. Velayos FS, Loftus EV Jr, Jess T et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006; 130: 1941-9. (Pubitemid 43816957)
9. Rutter MD, Saunders BP, Wilkinson KH et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004; 53: 1813-6. (Pubitemid 39556902)
10. Askling J, Dickman PW, Karlen P et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 2001; 120: 1356-62. (Pubitemid 32322309)
11. Casparie MK, Tiebosch ATMG, Burger G et al. Pathology databanking and biobanking in The Netherlands a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 2007; 29: 19-24. (Pubitemid 46535194)
12. Stolk EA, Rutten FF. The "health benefi t basket " in the Netherlands. Eur J Health Econ 2005: (Suppl): 53-7.
13. Oostenbrink JB, Rutten FF. Cost assessment and price setting of inpatient care in The Netherlands. The DBC case-mix system. Health Care Manag Sci 2006; 9: 287-94. (Pubitemid 44198214)
14. Van BL, Goossen WT, Van der Kloot WA. Linking nursing care to medical diagnoses: heterogeneity of patient groups. Int J Med Inform 2005; 74: 926-36. (Pubitemid 41570162)
15. www.dbconderhoud.nl. 2010. Ref Type: Internet Communication.
16. DBC zorg. DBC Registratie-, validatie- en declaratiemodel, 2004, versie 2.2. Ministerie Van Volksgezondheid 2004.
17. Nederlandse zorgautoriteit, Waarborgen NZa voor DIS-beheer met het oog op publieke taakuitoefening DBC ' s. Nederlandse zorgautoriteit, 2007.
18. Steyerberg EW, Eijkemans MJ, Harrell FE Jr et al. Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med 2000; 19: 1059-79. (Pubitemid 30238915)
19. Harrell FE Jr. Regression modeling Strategies. Springer-Verlag: New York, 2001.
20. Rubin DR, Schenker N. Multiple imputation in health-care databases: an overview and some applications. Stat Med 1991; 10: 585-698.
21. Palli D, Trallori G, Bagnoli S et al. Hodgkin ' s disease risk is increased in patients with ulcerative colitis. Gastroenterology 2000; 119: 647-53.
22. Jess T, Loftus EV Jr, Velayos FS et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted county, Minnesota. Gastroenterology 2006; 130: 1039-46.
23. Winther KV, Jess T, Langholz E et al. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004; 2: 1088-95. (Pubitemid 40037640)
24. Jess T, Winther KV, Munkholm P et al. Intestinal and extra-intestinal cancer in Crohn ' s disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther 2004; 19: 287-93. (Pubitemid 38253503)
25. Terdiman JP, Steinbuch M, Blumentals WA et al. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 367-71. (Pubitemid 46668239)
26. Bernstein CN, Blanchard JF, Kliewer E et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001; 91: 854-62. (Pubitemid 32173312)
27. Lutgens MW, Vleggaar FP, Schipper ME et al. High frequency of early colorectal cancer in inflammatory bowel disease. Gut 2008; 57: 1246-51.
28. Van Rijn AF, Fockens P, Siersema PD et al. Adherence to surveillance guidelines for dysplasia and colorectal carcinoma in ulcerative and Crohn ' s colitis patients in the Netherlands. World J Gastroenterol 2009; 15: 226-30.
29. Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18 (Suppl 2): 1-5. (Pubitemid 37174709)
30. Kiesslich R, Fritsch J, Holtmann M et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003; 124: 880-8. (Pubitemid 36389789)
31. Kleer CG, Appelman HD. Ulcerative colitis: patterns of involvement in colorectal biopsies and changes with time. Am J Surg Pathol 1998; 22: 983-9. (Pubitemid 28364498)
32. Riley SA, Mani V, Goodman MJ et al. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32: 174-8.
33. Geboes K, Ectors N, D ' Haens G et al. Is ileoscopy with biopsy worthwhile in patients presenting with symptoms of inflammatory bowel disease? Am J Gastroenterol 1998; 93: 201-6. (Pubitemid 29063967)
34. Rubin DT, Cruz-Correa MR, Gasche C et al. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis 2008; 14: 265-74. (Pubitemid 351288050)
35. Van Staa TP, Card T, Logan RF et al. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 2005; 54: 1573-8. (Pubitemid 41531774)
36. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005; 100: 1345-53. (Pubitemid 40904360)
37. Chan EP, Lichtenstein GR. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am 2006; 35: 675-712. (Pubitemid 44314185)
38. Bernstein CN, Blanchard JF, Metge C et al. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol 2003; 98: 2784-8. (Pubitemid 38020124)
39. Munkholm P, Loftus EV Jr, Reinacher-Schick A et al. Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates 1. Digestion 2006; 73: 11-9. (Pubitemid 43800656)
40. Baars JE, Zelinkova Z, Mensink PB et al. High therapy adherence but substantial limitations to daily activities amongst members of the Dutch inflammatory bowel disease patients ' organization: a patient empowerment study. Aliment Pharmacol Ther 2009; 30: 864-72.
41. Onizawa M, Nagaishi T, Kanai T et al. Signaling pathway via TNFalpha/ NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. Am J Physiol Gastrointest Liver Physiol 2009; 296: G850-9.
42. Rubin DT, Djordjevic A, Huo D. Use of 5-ASA is associated with decreased risk of dysplasia and colon cancer in ulcerative colitis. Gastroenterology 2003; 124: A279.
43. Zafar SY, Abernethy AP, Abbott DH et al. Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems. BMC Cancer 2008; 8: 345.
44. Jemal A, Siegel R, Ward E et al. Cancer statistics 2007. CA Cancer J Clin 2007; 57: 43-66.
45. Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2004; CD000279 .